CURRENT APPROACHES TO THE DIAGNOSIS AND MANAGEMENT OF ADOLESCENT PATIENTS WITH POLYCYSTIC OVARY SYNDROME


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Polycystic ovary syndrome (PCOS) manifests itself in adolescence and occurs in 2.2-7.5% of patients and in as high as 68% of girls with dysmenorrhea and hirsutism. PCOS is a chronic disease that is the most common cause of anovulatory infertility in young women. The etiology and the pathogenesis of this heterogeneous disease remain fully uninvestigated. The existing treatment options have no long-term effect. This paper summarizes the currently known characteristic features of the clinical manifestations of adolescent PCOS and present-day approaches to its diagnosis and management.

Full Text

Restricted Access

About the authors

Elena P. Khaschenko

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: khashchenko_elena@mail.ru
a graduate student of 2nd gynecological department (gynecology of children and youth) Moscow 117997, Ac. Oparina str. 4, Russia

Elena V. Uvarova

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: elena-uvarova@yandex.ru
MD, Professor, Head of the 2nd gynecological department (gynecology of children and youth) Moscow 117997, Ac. Oparina str. 4, Russia

References

  1. Уварова Е.В. Детская и подростковая гинекология. Руководство для врачей. М.: Литтерра; 2009. 238 с.
  2. Ndefo U.A., Eaton A., Green M.R. Polycystic ovary syndrome: a review of treatment options with a focus on pharmacological approaches. P&T Journal. 2013; 38(6): 336-8.
  3. Shayya R., Chang R.J. Reproductive endocrinology of adolescent polycystic ovary syndrome. Br. J. Obstet. Gynecol. 2010; 117(2): 150-5.
  4. Deligeoroglou E., Vrachnis N., Athanasopoulos N., Iliodromiti Z., Sifakis S., Iliodromiti S. et al. Mediators of chronic inflammation in polycystic ovarian syndrome. Gynecol. Endocrinol. 2012; 28(12): 974-8.
  5. Elting M.W., Korsen T.J., Rekers-Mombarg L.T., Schoemaker J. Women with polycystic ovary syndrome gain regular menstrual cycles when ageing. Hum. Reprod. 2000; 15(1): 24-8.
  6. Fauser Bart C.J.M., Tarlatzis B.C., Rebar R.W., Legro R.S., Baien A.H., Lobo R. et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS. Consensus Workshop Group. Fertil. Steril. 2012; 97(1): 28-38. e25.
  7. Sathyapalan T., Atkin S.L. Mediators of inflammation in polycystic ovary syndrome in relation to adiposity. Mediators Inflamm. 2010; 2010: 758656.
  8. Solomon C.G., Hu F.B., Dunaif A., Rich-Edwards J., Willett W.C., Hunter D.J. et al. Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus. JAMA. 2001; 286(19): 2421-6.
  9. Van Hooff M.H., Voorhorst F.J., Kaptein M.B., Hirasing R.A., Koppenaal C., Schoemaker J. Polycystic ovaries in adolescents and the relationship with menstrual cycle patterns, luteinizing hormone, androgens, and insulin. Fertil. Steril. 2000; 74(1): 49-58.
  10. Repaci A., Gambineri A., Pasquali R. The role of low-grade inflammation in the polycystic ovary syndrome. Mol. Cell. Endocrinol. 2011; 335(1): 30-41.
  11. Solorzano C.B., McCartney C.R., Blank S.K., Knudsen K.L. Hyperandrogenemia in adolescent girls: origins of abnormal GnRH secretion. Br. J. Obstet. Gynecol. 2010; 117(2): 143-9.
  12. Park A.S., Lawson M.A., Chuan S.S., Oberfield S.E., Hoeger K.M., Witchel S.F., Chang R.J. Serum anti-Mullerian hormone concentrations are elevated in oligomenorrheic girls without evidence of hyperandrogenism. J. Clin. Endocrinol. Metab. 2010; 95(4): 1786-92.
  13. Vilmann L.S., Thisted E., Baker J.L., Holm J.C. Development of obesity and polycystic ovary syndrome in adolescents. Horm. Res. Paediatr. 2012; 78(5-6): 269-78.
  14. Bonny A.E., Appelbaum H., Connor E.L., Cromer B., DiVasta A., Gomez-Lobo V. et al. Clinical variability in approaches to polycystic ovary syndrome. J. Pediatr. Adolesc. Gynecol. 2012; 25: 259-61.
  15. Lucky A.W., Biro F.M., Daniels S.R., Cedars M.I., Khoury P.R., Morrison J.A. The prevalence of upper lip hair in black and white girls during puberty: a new standard. J. Pediatr. 2001; 138(1): 134-6.
  16. Hardy T.S.E., Norman R.J. Diagnosis of adolescent polycystic ovary syndrome. Steroids. 2013; 78(8): 751-4.
  17. Cirik D.A., Dilbaz B. What do we know about metabolic syndrome in adolescents with PCOS? J. Turk. Ger. Gynecol. Assoc. 2014; 15(1): 49-55.
  18. Villarroel C., Merino P.M., Lopez P., Eyzaguirre F.C., Van Velzen A., Iniguez G., Codner E. Polycystic ovarian morphology in adolescents with regular menstrual cycles is associated with elevated anti-Mullerian hormone. Hum. Reprod. 2011; 26(10): 2861-8.
  19. Carmina E., Oberfield S.E., Lobo R.A. The diagnosis of polycystic ovary syndrome in adolescents. Am. J. Obstet. Gynecol. 2010; 203(3): 201. e1-5.
  20. Escobar-Morreale H.F., Carmina E., Dewailly D., Gambineri A., Kelestimur F., Moghetti P. et al. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Hum. Reprod. Update. 2012; 18(2): 146-70.
  21. Homburg R., Ray A., Bhide P., Gudi A., Shah A., Timms P., Grayson K. The relationship of serum anti-Mullerian hormone with polycystic ovarian morphology and polycystic ovary syndrome: a prospective cohort study. Hum. Reprod. 2013; 28(4): 1077-83.
  22. Iliodromiti S., Kelsey T.W., Anderson R.A., Nelson S.M. Can anti-Müllerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-analysis of extracted data. J. Clin. Endocrinol. Metab. 2013; 98(8): 3332-40.
  23. Буралкина Н.А., Уварова Е.В. Параметры овариального резерва девочек 15-17 лет с гармоничным половым и физическим развитием. Репродуктивное здоровье детей и подростков. 2010; 32(3): 20-8.
  24. Anderson E.L., Fraser А., McNally W., Sattar N., Lashen H., Fleming R. et al. Anti-Müllerian hormone is not associated with cardiometabolic risk factors in adolescent females. PLoS One. 2013; 8(5): e64510.
  25. Дедов И.И., Мельниченко Г.А. Синдром поликистозных яичников. М.: МИА; 2007. 368 с.7
  26. Duleba A.J., Dokras A. Is PCOS an inflammatory process? Fertil. Steril. 2012; 97(1): 7-12.
  27. Fulghesu A.M., Sanna F., Uda S., Magnini R., Portoghese E., Batetta B. Il -6 serum levels and production is related to an altered immune response in polycystic ovary syndrome girls with insulin resistance. Mediators Inflamm. 2011; 2011: 389317.
  28. Mohamed-Hussein Z.A., Harun S. Construction of a polycystic ovarian syndrome (PCOS) pathway based on the interactions of PCOS-related proteins retrieved from bibliomic data. Theor. Biol. Med. Model. 2009; 6: 18-31
  29. Чернуха Г.Е. Современные представления о синдроме поликистозных яичников. Consilium medicum. 2002; 4(8, приложение): 123-6
  30. Legro R.S., Arslanian S.A., Ehrmann D.A., Hoeger K.M., Murad M.H., Pasquali R., Welt C.K. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 2013; 98(12): 4565-92.
  31. Прилепская В.Н., Межевитинова Е.А., Иванова Е.В., Сасунова Р.А. Контрацепция и возможности персонифицированного подхода к ее назначению в различные возрастные периоды женщины. Фарматека. 2014; 4: 6-10.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies